Sunitinib is an oral multi-targeted tyrosine kinase inhibitor with activity against KIT and PDGFRA as well as other pathways that may be relevant in GIST, such as vascular endothelial growth factor receptor[53,54]. The gene discussed is PDGFRA; the disease is gastrointestinal stromal tumor.